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INTRODUCTION
Glioblastoma multiforme (GBM, WHO grade 
IV) is the most common primary brain tumor and it is 
invariably fatal [1]. Surgical resection combined with 
non-specific standard of care temozolomide chemotherapy 
and radiotherapy fail to eliminate completely tumor cells, 
resulting in a poor prognosis of less than 15 months 
in patients with this cancer [2]. Major reasons for 
treatment failure include the highly infiltrative growth 
pattern of GBM and chemo- and radio-resistance 
[3, 4]. Consequently, new effective strategies that can 
eliminate the residual tumor cells are urgently needed. 
Immunotherapy offers a precise approach for specifically 
targeting residual glioblastoma cells with reduced risk of 
collateral toxicity [5]. Some suitable glioma-specific cell 
surface antigens have been identified, such as the EGF 
receptor (EGFR) and its variant EGFRvIII, HER2/neu, 
IL-13 receptor alpha chain 2 [6], and the EPH receptor 
A2 (EphA2) [7]. Malignant gliomas are, however, highly 
heterogeneous tumors. This property gives them the 
capacity for immune escape, with the subsequent high-
risk of recurrence of antigen-negative tumors [8]. Given 
these limitations, the identification of new tumor-specific 
antigens is necessary.
We have previously generated a mouse monoclonal 
antibody (mAb) that is specific for the O-acetylated 
derivative of the neuroblastoma-associated tumor antigen 
ganglioside GD2 [9]. Gangliosides represent a family of 
sialic acid-containing glycosphingolipids that are anchored 
in the plasma membrane by a lipophilic ceramide segment, 
with the antigenic carbohydrate section extending into the 
extracellular region. Through protein binding, gangliosides 
activate responsiveness of various signaling proteins (for 
a review see [10]). GD2, a b-series disialoganglioside, 
is highly expressed in neuroblastoma and several mAbs 
against GD2 have been developed in treatment of this 
cancer [11]. GD2 is also expressed in gliomas [12], but 
also in some normal structures of the brain [12]. This 
property limits its interest as a specific tumor antigen 
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ABSTRACT
There are still unmet medical needs in the treatment of glioblastoma, the 
most common and the most aggressive glioma of all brain tumors. Here, we found 
that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. 
In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat 
GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken 
together, these results indicate that O-acetylated GD2 represents a novel antigen for 
immunotherapeutic-based treatment of high-grade gliomas.
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for glioblastoma immunotherapy [13]. Interestingly, we 
have previously found that the O-acetylated derivative 
of GD2—O-acetyl-GD2 (OAcGD2)—is not detected in 
normal brain tissue [13]. However, the distribution of this 
antigen in GD2-expressing brain tumors remains largely 
unknown. Here we explored the usefulness of OAcGD2 
as a potential tumor antigen for immune-based therapy in 
patients with malignant glioma. We report that OAcGD2 
is specifically expressed in glioblastoma and further 
demonstrate the in vitro and in vivo anti-glioma properties 
of anti-OAcGD2 mAb. 
RESULTS
Ganglioside OAcGD2 is expressed on human 
glioblastoma 
We reported earlier that OAcGD2 expression 
is absent in brain tissue [13]. Here, we investigated 
the expression of OAcGD2 in 35 glioblastomas from 
35 patients. This panel was obtained from the IRCNA 
Tumor Bank (Saint-Herblain, France). We performed 
immunohistochemical staining using 8B6 mAb specific 
for OAcGD2 on frozen tumor tissue sections. We next 
graded qualitatively the intensity of OAcGD2 staining 
compared with positive and negative control samples 
(Figure 1). Figure 1 shows positive (brown) 8B6 
staining in 3 human glioma samples with 3+, 2+ and 
1+ immunochemical intensity. We detected positive 
staining in all 35 glioma tumor samples studied (Table 1, 
Supplementary Figure S1). Nine tumors (25.7%) 
demonstrated 1+ immunochemical intensity, 17 tumors 
(48.6%) demonstrated 2+ intensity, and nine tumors 
(25.7%) demonstrated 3+ intensity. The data showed no 
correlation between the OAcGD2-expression level and 
the age or the sex of the patients (Table 1). These results 
show that expression of OAcGD2 can serve as a marker 
of glioblastoma. 
Anti-OAcGD2 mAb binds to primary glioma 
biopsy-derived cells and glioma cell lines 
We next characterized the expression levels of 
OAcGD2 by flow cytometry in 3 glioma- and 9 patient-
derived glioma cells. We established these primary GBM 
cells from patients with glioblastoma undergoing surgery 
at G. Laennec Nantes University Hospital (Nantes). 
Figure 2 shows the flow charts of the comparative binding 
of mAb 8B6 on the patient-derived glioma cells DUASO 
II, the human U251- and human A172 cell lines. The data 
obtained with the other studied glioma cells are presented 
in Supplementary Figure S2 and in Table 2. We found that 
all studied primary glioma biopsy-derived cells and GBM 
cell lines expressed OAcGD2 ganglioside. We observed 
no binding of control antibody to glioma cells, confirming 
the specificity of mAb 8B6 staining (Figure 2). Analyses 
of the MFI ratios indicated that the patient-derived glioma 
cells expressed higher level of OAcGD2 than the GBM 
cell lines (Figure 2, Table 2).
Antibody 8B6 induces tumor cell death of 
OAcGD2-expressing glioma cells in vitro
We next sought to determine whether mAb 
8B6 could inhibit glioma cell growth. To assess this 
question in vitro, we first determined the tumor cell 
viability after mAb 8B6 treatment using a MTT assay 
(Figure 3, left column panels). We included a control 
antibody to ensure that the observed results were antigen 
specific. We observed an inhibition of tumor cell viability 
induced by mAb 8B6 in seven of the 12 studied GBM 
cells (58%) (Figure 3, Table 2). In sensitive cells, the cell 
viability reduction induced by mAb 8B6 was dose- and 
time-dependent (data not shown). For the U251 cell line, 
the effect became statistically significant after 24 hours at 
25 µg/mL (p < 0.05), as compared to control antibody-
treated cells (Figure 3A). The highest inhibitory effect 
was exerted by the antibody concentration of 50 µg/mL. 
This treatment resulted in a ~20% decreased in U251 cell 
viability (Figure 3A). Similarly, viability of A172 
(Figure 3B), DUASO II (Figure 3C), LN18 (Table 2), 
AMBMA (Table 2), and GUITH (Table 2) cells was also 
significantly reduced with mAb 8B6 compared to control 
antibody (p < 0.05). We further tested mAb 8B6 ability to 
induce GBM cell death by staining the tumor cells with 
propidium iodide followed by flow cytometry analysis. 
We show in Figure 3, right column panels, the results 
obtained with mAb 8B6 when the cells were treated with 
50 µg/ ml for 24 hours. Antibody 8B6 induced cell death in 
the 3 tested GBM cell types. On the other hand, the control 
antibody did not affect the cell viability compared to the 
untreated cells. We also found that mAb 8B6-induced 
cell death was associated with an increased percentage of 
annexin V positive cells (Supplementary Figure S3) and 
the activation of caspase 3 (Supplementary Figure S4) in 
comparison to control antibody-treated- and untreated-
cells. Interestingly, the effects of mAb 8B6 on glioma 
cell viability were partially blocked by pre- treatment 
of the tumor cells with the pan-caspase inhibitor 
zVAD- fmk (Supplementary Figure S4). This suggests 
that the observed effects were, at least in part, caspase-
dependent. Overall, these results show that mAb 8B6 
induces GBM cell death independently of immunological 
mechanisms via the caspase-3-dependent pathway and 
some independent pathways.
Antibody 8B6 induces immune effector activity 
against OAcGD2-expression glioma cells 
Immune effector activity is an important mechanism 
of antibody against cancer cells and, in particular, 
antibody-dependant cell cytotoxicity (ADCC) has been 
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implicated in the clinical efficacy of anti-ganglioside 
antibody [14, 15]. Thus, we studied the effect of mAb 
8B6 on ADCC activity against the OAcGD2-expressing 
glioma biopsy-derived tumor lines. To this end, glioma 
cells were labeled with the PKH-26 membrane dye, and 
incubated with various concentrations of mAb 8B6. The 
NK-92-RFcγIII+ cells were used as effector cells. After 
incubation, cell death within the PKH-26+ target cell 
population was detected by the addition of the viability 
probe TP3. We observed ADCC with mAb 8B6 against the 
U251, the A172 and the DUASO tumor cells (Figure 4). 
We found a correlation between ADCC activity and both 
the concentration of antibody and the E/T ratio (Figure 4). 
Specific lysis achieved maximum values in the 3 studied 
cell types at an E/T ratio of 1/12.5 with 10 µg/ml mAb 
8B6. We demonstrated the specific lysis by comparing 
the ADCC results of mAb 8B6 with the control antibody, 
which showed only background lysis. We found similar 
results with the LN18 cell line and the 8 other studied 
patient-derived GBM cells (Table 2).
To this end, we incubated the OAcGD2-expressing 
target cells with mAb 8B6 in the presence of diluted 
human serum, which provided complement. Cell death 
was assessed by the addition of the viability probe 
propidium iodide. We found that mAb 8B6 induced CDC 
towards the DUASO tumor-derived cells (Figure 5). 
We observed a correlation between cytotoxicity and both 
the concentration of antibody (panel A) and the serum 
ratio (panel B). Specific lysis achieved maximum values of 
36.6 ± 0.2% with mAb 8B6, at 10 µg/ml and serum ratio 
of 10%. We demonstrated the specific lysis by comparing 
the CDC results of mAb 8B6 with the non-specific control 
antibody, which showed only background lysis. We 
obtained similar results with the AMBMA primary cells 
(Table 2). We found that the U251 (Figure 5C) and the 
A172 cell lines (Figure 5E) were resistant to CDC induced 
by mAb 8B6. These two cell lines expressed the inhibitors 
of complement activation CD55 (Figure 5D) and CD59 
(Figure 5F). The BAUJE, COXCA, GBMAI, Glio 5 and 
HOUHE GBM primary cells were also resistant to CDC 
induced by mAb 8B6 (Table 2). Taken all together, these 
data suggest that ADCC is the main mAb 8B6 GBM 
killing mechanism.
Antibody 8B6 to OAcGD2 inhibits glioma 
xenograft growth
We next investigated the effect of anti-
OAcGD2 mAb 8B6 on glioblastoma growth. We used a 
subcutaneous U251 human glioblastoma xenograft model. 
When tumors reached 150 mm3, we treated the mice with 
a single i.v. injection of 250 µg mAb 8B6 and followed 
Figure 1: OAcGD2 staining of glioma frozen tissue sections. Panel (1) is demonstrating a representative picture of negative 
control (glioma tissue stained with non-specific mAb), panel (2) a representative picture of positive control (glioma tissue stained with anti-
GD2 14G2a), panel (3) a representative picture of a 1+ positive glioma sample, panel (4) a representative picture of a 2+ positive glioma 
sample, and panel (5) a representative picture of a 3+ positive glioma sample. Scale bar = 100 µm.
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Table 1: Expression of OAcGD2 in glioblastomas
N° Sex Age Type 8B6 mAb staininga
1 M 69 IV 1+
2 F 45 IV 1+
3 M 62 IV 1+
4 F 78 IV 1+
5 M 62 IV 1+
6 M 46 IV 1+
7 M 66 IV 1+
8 F 64 IV 1+
9 F 48 IV 1+
10 F 37 IV 2+
11 M 64 IV 2+
12 M 46 IV 2+
13 M 77 IV 2+
14 M 72 IV 2+
15 F 68 IV 2+
16 F 73 IV 2+
17 M 61 IV 2+
18 M 65 IV 2+
19 M 61 IV 2+
20 F 59 IV 2+
21 F 69 IV 2+
22 F 67 IV 2+
23 F 69 IV 2+
24 M 74 IV 2+
25 F 65 IV 2+
26 M 58 IV 2+
27 M 66 IV 3+
28 M 68 IV 3+
29 F 49 IV 3+
30 M 59 IV 3+
31 F 58 IV 3+
32 F 57 IV 3+
33 F 61 IV 3+
34 F 54 IV 3+
35 M 74 IV 3+
a The staining intensity of the glioma tissues was graded as 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong) after 
immunohistochemical staining with mAb 8B6, as described in the Materials and Methods section.
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tumor growth. We also included a control antibody-treated 
group to demonstrate the specificity of the mAb 8B6-
therapy. As shown in Figure 6A, mAb 8B6 significantly 
inhibited the tumor growth. The tumor volume at 
day 90 after antibody injection, volumes averaged 
1023 ± 240 mm3, 810 ± 195 mm3, and 346 ± 59 mm3 when 
the mice were treated respectively with vehicle (PBS 
group), with CTL-IgG (control group) or mAb 8B6. In 
this context, mAb 8B6 injection resulted in a significant 
increase of the U251 tumor doubling time, compared to 
both PBS- and CTL-IgG-treated group (Supplementary 
Figure S5, p < 0.05). The antibody treatment did not 
induce any body weight loss during the experiment 
(Figure 6B). Taking into consideration that specific 
immunotherapy can result in antigen-negative tumor 
recurrence [16], we next analyzed OAcGD2 expression 
in the recurrent U251 xenograft in the 8B6-mice treated 
group. We found that biotinylated-8B6 mAb stained 
strongly U251-tumor sections similarly in mice treated 
with either mAb 8B6 or control antibody (Figure 6C). 
In contrast, we could not detect any labeling with the 
biotinylated-control antibody (Figure 6C). Taken together 
these results show that anti-OAcGD2 immunotherapy 
inhibits OAcGD2-expressing glioblastoma tumor growth 
without down-regulating OAcGD2 expression on tumor 
cells.
DISCUSSION
Here, we exploited the availability of a panel of 
human glioma surgical specimens to characterize their 
OAcGD2 status. We observed OAcGD2 positivity in 
the 35 patients: 9 patients (26%) displayed 1+ tumors, 
17 patients (49%) 2+ tumors, and 9 (26%) 3+ tumors. 
We also found three cell lines and nine primary glioma 
tumor cells expressing OAcGD2. Important in the 
consideration of OAcGD2 as a potential molecular 
antigen for immunotherapy, we reported earlier that 
no comparable immune reactivity could be observed 
in normal brain or in peripheral nerves [13]. Thus, the 
immune reactivity throughout the entire studied panel 
of glioma biopsies for mAb 8B6 supports the clinical 
use of therapeutic antibody specific for OAcGD2. To 
the best of our knowledge this is the first investigation 
describing the expression of OAcGD2 in tumor surgical 
samples [17].
Figure 2: The expression levels of OAcGD2 on the A172 cell line (A), the U251 cell line (B), and on the DUASO II 
tumor-derived cells (C) were studied by flow cytometry as indicated. Tumor cells were stained with mAb 8B6 as described in 
the Materials and Methods section. The histograms of the cells stained with mAb 8B6 and isotype control are shown in white and black, 
respectively. (D) Comparison binding of mAb 8B6 on DUASO II, A172 and U251 cells. Results are presented as MFI ratios calculated 
by using geometric mean values of the MFI as indicated in the Materials and Methods section. Data are expressed as mean ± SD (n = 3 
independent experiments with similar design).
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To confirm that OAcGD2 ganglioside is a 
suitable antigen for glioblastoma immunotherapy, we 
next studied the anti-glioblastoma activity of the mAb 
8B6 specific for OAcGD2 ganglioside. Our results 
showed that glioblastoma cells expressing OAcGD2 can 
be killed by mAb 8B6 by three different mechanisms 
in vitro: (1) induction of a non-immunologic direct 
cytotoxicity involving at least caspase-3, (2) induction of 
antibody-dependent cell cytotoxicity, and (3) induction 
of complement cellular cytotoxicity. Here, we found 
that most of the studied glioblastoma cell lines and 
glioblastoma tumor-derived cells were resistant to CDC 
in our in vitro experiments. We explained the lack of effect 
to the overexpression in these cells of the two complement 
inhibitors CD55 and CD59, as shown in our flow 
cytometry analyses. Surprisingly, the non-immunologic 
direct cytotoxicity, which we described earlier in 
neuroblastoma cells [18], occurred in only 58% of the 
studied glioblastoma cellular models. These data warrant 
further studies to define the molecular mechanisms that 
confer tumor cell resistance to apoptosis induced by anti-
OAcGD2 mAbs. We also demonstrated that mAb 8B6 
induces ADCC against glioblastoma cells. This capacity 
should be considered as important feature goal for anti-
OAcGD2 immunotherapy. For example, the development 
of engineered cytotoxic T-cells expressing a chimeric 
antigen receptor specific for OAcGD2 may be a better 
choice to strengthen glioblastoma immunotherapy than 
a stand alone antibody therapy [19]. Due to its exquisite 
tumor-specificity [13], OAcGD2 could also represent an 
ideal antigen for chimeric antigen receptor-based cellular 
therapies.
Finally, to support our findings in vitro, we evaluated 
the efficacy of mAb 8B6 in inhibiting the growth of 
established subcutaneous U251 human glioblastoma 
xenografts. Similar to our in vitro data, a therapeutic effect 
was obtained in vivo. The anti-OAcGD2 mAb 8B6 was 
able to delay tumor growth of animals with subcutaneous 
established U251 glioma xenograft. Taking into account 
that therapeutic antibody attack can select antigen-negative 
clones with subsequent high-risk of recurrence of antigen-
negative tumors, we assessed OAcGD2 expression in the 
recurrent tumor of mAb 8B6 treated mice 90 days after 
antibody injection. Loss of glioblastoma antigen expression 
upon specific immunotherapy was recently illustrated in an 
immunization study against EGFRvIII [8]. Patients with 
initial response ultimately showed recurrence of EGFRvIII-
negative tumor [8]. Here, we found that OAcGD2 expression 
was persistent in the U251 xenografts post-immunotherapy. 
This observation is consistent with an earlier study 
concerning the persistence of the neuroblastoma-associated 
ganglioside GD2 antigen after anti-GD2 therapeutic 
Table 2: In vitro anti-tumor properties of mAb 8B6 against GBM cells
Tumor cells OAcGD2 
expressiona
Direct cytotoxicityb CDCc ADCCd
Tumor-derived GBM cells
AMBMA 22.2 13.3 ± 1.4 17.6 ± 1.1 11.9 ± 1.0
BAUJE 52.2 0 0 20.0 ± 0.4
BICYY 12.2 0 0 23.5 ± 1.2
COXCA 24.2 0 0 22.3 ± 1.9
GBMAI 4.6 0 0 26.3 ± 2.1
Glio 5 29.7 8.7 ± 1.2 0 39.5 ± 3.7
GUITH 14.3 11.4 ± 1.0 0 37.8 ± 1.3
HOUHE 9.4 0 0 19.0 ± 0.5
Cell lines
LN18 4.2 10.6 ± 0.9 0 8.6 ± 0.7
a Determined by flow cytometry experiments using an immunofluorescent staining with mAb 8B6, as described in the Materials 
and Methods section.
bDetermined as tumor viability inhibition (%) by MTT assays after 24 hours incubation with mAb 8B6 (50 µg/mL).
c Determined as tumor cell lysis (%) by flow cytometry experiments after incubation for 4 hours with mAb 8B6 (10 µg/mL) 
with 20% of human serum.
d Determined as tumor cell lysis (%) by flow cytometry experiments after incubation for 24 hours with mAb 8B6 (10 µg/mL) 
at an E/T ratio of 1/12.5 with 10 µg/ml of mAb 8B6.
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Figure 3: Antibody 8B6 decreases cell viability of OAcGD2-expressing glioblastoma cells. Left column panels, U251 (A), 
A172 (B), and DUASO II (C) cells were treated for 24 hours with various concentrations of mAb 8B6 (○) and a control antibody (●). 
Viability was assessed as described in the Materials and Methods section by adding the methylthiazole tetrazolium salt during 4 hours 
(MTT assay). Absorbance was recorded at 570 nm. The data are presented as mean ± SD for three independent experiments, each in 
quadruplicate (*p < 0.05). Right column panels, cell viability after 24 hours of incubation with mAb 8B6 was evaluated by propidium 
iodide uptake and flow cytometry analysis. Cytotoxicity is expressed as percentage of propidium iodide-stained cells. Isotype-matched 7H2 
antibody was used as a negative control as indicated. Bars represent mean of triplicate measurements; SD are shown.
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Figure 4: ADCC activity of mAb 8B6 (○) was determined against the OAcGD2-positive glioblastoma cells U251 (A), 
A172 (B) and DUASO II (C). Left columns, effect of varying antibody concentration at effector to target cell ratio of 12.5 to 1. Right 
columns, effect of varying effector to target ratio at antibody concentration of 10 µg/ml. The results were compared to the effect of equal 
amounts of the isotype-matched control IgG (●). Results are presented as mean ± SD of triplicate sample in a representative experiment. 
Similar results were obtained in three independent experiments.
Oncotarget9www.impactjournals.com/oncotarget
Figure 5: CDC activity of mAb 8B6 (○) at varying antibody concentrations against DUASO II cells (A, B), U251 cells 
(C), and A172 cells (E). CDC activity of mAb 8B6 (○) (10 µg/ml) was assessed against the OAcGD2 positive DUASO II tumor-derived 
cells at varying serum ratios. The results were compared to the effect of equal amounts of control antibody used as a negative control (●). 
Results are presented as mean ± SD. The expression of the inhibitors of complement activation, CD55 (D) and CD59 (F), on the CDC-
resistant glioblastoma cell lines, U251 (bold line) and A172 (grey line), was analyzed by flow cytometry. The cells stained with the isotype 
control antibody are shown in black.
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antibody therapy [20]. This stable expression of OAcGD2 
on GBM tumors is an important prerequisite for OAcGD2-
directed immunotherapies. Hence, as a specific glioblastoma 
antigen, OAcGD2 has many attractive properties, including 
high tumor density, homologous tumor cell expression, and 
expression persistence post-immunotherapy. 
In conclusion, we have reported that OAcGD2 
ganglioside is expressed at high levels in glioblastoma 
tumor and that mAb 8B6 specific for OAcGD2 efficiently 
inhibits glioblastoma growth. These results warrant the 
development of antibody constructs for application in 
immunotherapy of GBM.
Figure 6: (A)  Anti-OAcGD2 mAb 8B6 inhibits glioblastoma tumor growth in vivo. Mice (n = 12) with established subcutaneous 
U251 human glioblastoma xenografts (average volume ~150 mm3) were treated with either PBS (■), control mAb (●), or mAb 8B6 (○). 
Tumor growth was monitored and mice were euthanized for ethical consideration once the tumor volume exceeded 1000 mm3, which was 
therefore considered the end point for each individual mouse. (B) Mean weight for each treatment group (■, PBS; ●, control antibody; ○, 
8B6 antibody). Mean weight of group of mice (n = 12) at day 0 was defined as 100% weight. Results are presented as mean ± SD. 
(C) Tumors were collected on day 90 after mAb 8B6 immunotherapy perfusion. Strong immunostaining with biotinylated-8B6 mAb was 
observed on U251 tumor cells in the mAb 8B6 treatment regimens. The control antibody was used as a negative control, as indicated. Three 
U251 tumor xenografts from 3 different mice in the 8B6 and the control antibody experimental group were tested with the same result 
respectively. Scale bar = 50 µm.
Oncotarget11www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Cell lines
Human glioblastoma (GBM) cell lines (U251, 
LN18, and A172) were obtained from the American Tissue 
Culture Collection (ATCC, USA). Cell lines were used for 
less than 6 months after resuscitation and were routinely 
tested for Mycoplasma by PCR. We did not conduct any 
genotypic authentication. U251 and A172 cell lines were 
cultured in DMEM 4, 5 g/l glucose, supplemented with 
10% fetal calf serum (FCS) and L-glutamine. LN18 cell 
line was cultured in DMEM 4, 5 g/l glucose, supplemented 
with 5% FCS and L-glutamine. All cell lines were cultured 
with 100 units/ml penicillin and streptomycin. All culture 
reagents were obtained from Gibco Life Technologies 
(Carlsbad, CA, USA). They were maintained in culture at 
37°C with 5% CO2.
Primary glioma biopsy-derived cells
Tumor specimens were collected from patients 
with a histologic diagnosis of GBM (WHO Grade IV 
astrocytoma). Confirmation of tumor diagnosis and 
grading was performed by neuro-pathologists at Nantes 
University Hospital (Nantes, France). Tumors were 
harvested at the time of surgical resection and immediately 
put into culture after dissociation of the tumors using 
the gentleMACs Dissociator (Miltenyi) according to 
the manufacturer’s instructions. All specimen collection 
and analysis were performed in accordance with the 
Institutional Review Board-approved protocol and all 
patients or their guardians provided written informed 
consent (Comité de Protection des Personnes Ouest IV, 
protocol # DC-2012-1555). The cells were maintained in 
an atmosphere of 5% CO2 and 95% humidity in defined 
medium (DMEM/Ham F12 containing 2 mM L-glutamine, 
100 U/mL penicillin, 100 µg/mL streptomycin, B27 
supplement, N2 supplement, 2 µg/ml heparin, 40 ng/ml 
ß-FGF and 40 ng/ml EGF) to form neurospheres. They 
were used at early passage. We conducted genotypic 
authentication using the CGH Array (ThermoFisher 
Scientific, Waltham, MA, USA). All the cell cultures were 
tested for Mycoplasma contamination by PCR before use. 
Antibodies 
Mouse IgG2a mAb 14G2a (γ2a, kappa) specific 
for GD2 was purchased from BD Biosciences (Franklin 
Lakes, NJ). Mouse IgG2a mAb 7H2, a gift from Dr. J. 
Portoukalian (Department of Dermatology, Edouard 
Herriot Hospital, University of Lyon, France) specific 
for O-acetyl-GD3, was used as a negative control. 
Mouse IgG2a anti-OAcGD2 mAb 8B6 was constructed 
by joining the complementary deoxyribonucleic acid for 
the variable region of the parental murine IgG3 antibody 
8B6 [9] with the mouse constant regions of the γ2a heavy 
chain and the kappa light chain. Appropriate light and 
heavy expression vectors were co-transfected into chinese 
hamster ovary (CHO-S) cells (Life Technologies). The 
resulting antibody was affinity-purified from culture 
supernatant using the Hitrap rProtein A FF column (GE 
Healthcare Bios-Sciences, Uppsala, Sweden). The protein 
A affinity chromatography step was followed by anion-
exchange chromatography on Sepharose Q for endotoxin 
removal. The purity of mAb preparations was verified by 
SDS-PAGE and size exclusion HPLC analyses. Endotoxin 
quantitation was evaluated using the LAL kinetic 
chromogenic assay (Lonza, Basel, Switzerland).
Immunohistochemistry on human glioblastoma 
samples
Glioblastoma tissues were provided by the Tumor 
Bank of the “Institut Régional du Cancer de Nantes 
Atlantique” (Nantes, France). Samples were obtained 
from patients at the time of surgery. All samples had 
≤ 50% necrosis to be able to accurately assess OAcGD2 
expression across specimens. All specimen collection 
and analysis were performed in accordance with the 
Institutional Review Board-approved protocol and all 
patients or their guardians provided written informed 
consent (Comité de Protection des Personnes Ouest IV, 
protocol # DC-2012-1555). Frozen tissue sections of 10 µm 
thickness were treated with ice-cold acetone, rehydrated 
with PBS and blocked with the Dako Real™ antibody 
diluent reagent (Dako, Glostrup, Denmark). Antibody 
8B6 was added onto the sections at a final concentration 
of 10 µg/ml for 1 hour. After washing, the bound mAb 
was detected by incubation of anti-mouse labeled polymer-
HRP (Dako). DAB was used as HRP substrate and sections 
were counterstained with hematoxylin before immune 
cytological evaluation. Anti-GD2 mAb 14G2a was used 
as a positive control and mAb 7H2 as a negative control. 
Slides were imaged with a Nanozoomer (Hamamatsu, 
Hamamatsu City, Japan). Images were stored as TIFF 
files with Adobe Photoshop. Staining was graded positive 
or negative according to the presence or the absence of 
immune reactivity, respectively. The intensity and location 
of tissue staining were assessed by a comparison with the 
positive and negative controls. Tissue was assessed and 
graded by 2 independent observers and assessments were 
re-reviewed by an anapathologist.
For detection of OAcGD2 in the U251 xenografts, 
we use biotinylated mAb 8B6. The mAb 8B6 was 
biotinylated using the EZ-Link Sulfo-NHS-LC-
Biotinylation kit (Pierce, Rockford, IL, USA) according 
to the manufacturer’s instructions. Ten micrometer-
sections of the U251 xenografts were blocked with 
the Dako Real™ antibody diluent reagent as described 
above (Dako, Glostrup, Denmark). We then added 8B6-
biotinylated mAb onto the sections at a final concentration 
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of 10 µg/ml for 1 hour. After rinsing, the bound mAb was 
detected by incubation with Streptavidin-HRP. DAB was 
used as HRP substrate and sections were counterstained 
with hematoxylin before immune cytological evaluation. 
Biotinylated-7H2 mAb was used as a negative control. 
Slides were imaged and pictures were stored as described 
above.
Analysis of cell-surface expression of OAcGD2 
by flow cytometry
Analysis of cell surface OAcGD2-expression on 
tumor cells was performed by indirect immunofluorescence 
measured by flow cytometry. Briefly, cells were incubated 
with either mAb 8B6 or 7H2 at 10 µg/mL for 60 min at 
4°C. Antibody binding was detected by incubation with a 
fluorescein isothiocyanate-labeled F(ab’)2 fragment of goat 
anti-mouse IgG (Jackson Immunoresearch, Soham, UK) 
for 60 min at 4°C. Cell fluorescence was analyzed using a 
FACSCalibur flow cytometer (BD Biosciences, San Jose, 
CA, USA) and CellQuestPro software (BD Biosciences). 
Relative fluorescence intensities of 10,000 cells were 
recorded as single-parameter histograms (log scale, 
1024 channels, and 4 decades) and mean fluorescence 
intensity (MFI) was calculated for each histogram. Results 
were expressed as the MFI ratio calculated by dividing the 
flow cytometric MFI value of cells stained with antigen-
specific mAb by the MFI value for the same cells stained 
with isotype-matched control antibody. This approach 
allows for comparison of multiple test samples between 
different groups.
Cell growth inhibition
Cell viability was measured using the MTT assay 
[21]. Cells (1 × 104) were suspended in 100 µL and 
incubated for 24 hours at 37°C, 5% CO2. Monoclonal 
antibodies were diluted in 50 µL specific medium and 
added to 96-well microplates (BD, Franklin Lakes, NJ, 
USA) to give a final concentration of 40, 20, 10, 5, 2.5, 
and 1.25 µg/mL. After incubation for 24 hours at 37°C, 
5% CO2, 10 µL methylthiazole tetrazolium (MTT) 
stock solution (5 mg/mL, Sigma Aldrich, Saint Louis, 
MO, USA) was added to each well and the plates were 
incubated at 37°C for 4 hours. Then, 100 µL 10% SDS 
were added and the plates were incubated for overnight at 
37°C for color development. Optical density was recorded 
at 570 nm and at 650 nm on a Multiskan reader (Thermo 
Electron, Walthman, MA, USA). 
Induction of cell death
Cells were seeded in 48-well culture plates and 
incubated with the antibodies (50 µg/ml) for 24 hours. 
Cells were washed, resuspended in PBS with propidium 
iodide (10 µg/ml; Sigma Aldrich) and analyzed by flow 
cytometry. Propidium iodide-stained cells were considered 
as dead cells. A quantitative measurement of dead cells 
was done by propidium iodide labeling histogram.
Complement dependent cytotoxicity (CDC)
Aliquots of tumor cells (2 × 104) were incubated 
with 80 µL antibody solution at various concentration 
in the presence of 20 µl human serum as complement 
source for 2 hours at 37°C. Cytotoxicity was determined 
within the tumor cell population after addition of the 
viability probe propidium iodide (PI; 10 µg/ml) using a 
FACSCalibur flow cytometer (BD Biosciences, San Jose, 
CA, USA) and CellQuestPro software (BD Biosciences). 
The percentage of specific lysis was calculated as: (% non-
viable PI+ 8B6-incubated tumor cells) – (% non-viable PI+ 
control antibody-incubated tumor cells).
Antibody-dependent cell cytotoxicity (ADCC) 
An ADCC assay was performed as reported 
previously [22]. Tumor cells were labeled with membrane 
dye PKH-26 (Sigma Aldrich, St. Louis, MO, USA) 
according to the manufacturer’s instructions. Aliquots of 
the labeled cells (1 × 104 cells/100 µl) were incubated 
with 50 µL antibodies in 96-well plates. The human NK-
92-RFcγIII+ cells were used as effector cells [23]. 50 µL 
NK-92-RFcγIII+ cells at the indicated effector-to-target 
ratio (E/T) were added to the tumor cells and incubated 
for 24 hours at 37°C. Cell death within the PKH-26+ 
target cell population was then assessed by the addition of 
TO-PRO-3 iodide (TP3) (Life Technologies, Grand Island, 
NY, USA). The double-positive TP3+ PKH26+ dead target 
cell population was detected by flow cytometry analysis 
using a FACSCalibur flow cytometry (BD Biosciences) and 
CellQuestPro software (BD Biosciences). The percentage 
of specific lysis was calculated as 100× (non-viable double-
positive target cells)/(non-viable double-positive target 
cells + viable PKH26+ target cells). The lysis of the NK-
sensitive mouse T cell lymphoma YAC-1 was used as an 
indicator of NK-92-RFcγIII+ activity [24].
Glioblastoma xenograft mouse model
Subcutaneous glioblastoma-bearing mice were 
obtained by s.c. flank injection of 5 × 106 U251 cells in 
8-week old female BALB/c nude mice obtained from 
Charles River Laboratories (Bois des Oncins, France). 
Subcutaneous tumor growth was measured at indicated 
days after tumor implantation using the formula 
[volume mm3 = (length) × (width)2 × 0.5]. Antibody 
(250 µg, one injection) was given i.v. when the tumor 
volume had reached ~0.1 cm3. For ethical considerations, 
mice had to be euthanized once tumor volume exceeded 
1,000 mm3, which was considered the end point for 
each individual mouse. The mean tumor doubling time 
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was calculated in each experimental group according to 
Schwartz, 1961 [25]. This study was carried out in strict 
accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the French 
Department of Agriculture (agreement number 44–278). 
The protocol was approved by the Committee on the 
Ethics of Animal Experiments of the Région Pays de la 
Loire (Permit Number: B4459).
Statistical analysis
Statistical analysis was performed using Prism 
software (GraphPad Prism Software, La Jolla, CA, 
USA). Results in the in vitro experiments were analyzed 
with the unpaired t-test and are given as mean ± SD. For 
in vivo experiments, results from mAb-treated group were 
compared with PBS- and CTL-IgG-treated group using 
the unpaired t-test and are given as mean ± SEM. A value 
p < 0.05 was considered to be significant. 
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